SalaryGuide
AboutPricingFor Employers

Marketing jobs

7 marketing jobs

Alkermes logo
2 days ago

Regional Brand Manager, Rare Disease - West

Alkermes

Los Angeles, CA (Remote)Full time$200K/yr – $220K/yr
Alkermes logo
2 days ago

Regional Brand Manager, Rare Disease - South Central / Midwest

Alkermes

Dallas, TX (Remote)Full time$200K/yr – $220K/yr
Alkermes logo
2 days ago

Regional Brand Manager, Rare Disease - Southeast / Mid-Atlantic

Alkermes

Miami, FL (Remote)Full time$200K/yr – $220K/yr
Alkermes logo
2 days ago

Regional Brand Manager, Rare Disease - Ohio Valley / Northeast

Alkermes

Boston, MA (Remote)Full time$200K/yr – $220K/yr
Alkermes logo
7 weeks ago

Associate Director, HCP Marketing, LUMRYZ (IH)

Alkermes

Waltham, MA (Hybrid)Full time$165K/yr – $190K/yr
Alkermes logo
4 months ago

Director, Thought Leader Engagement Marketing

Alkermes

Waltham, MA (Hybrid)Full time$177K/yr – $210K/yr
Alkermes logo
4 months ago

Intern, Vivitrol Marketing

Alkermes

Waltham, MA (Hybrid)Full time$21/hr – $24/hr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

7 jobs
Alkermes logo

Regional Brand Manager, Rare Disease - West

Alkermes

Los Angeles, CA (Remote)

$200K/yr - $220K/yrIn-houseFull-timeMid level
2 days ago
Alkermes logo

Regional Brand Manager, Rare Disease - South Central / Midwest

Alkermes

Dallas, TX (Remote)

$200K/yr - $220K/yrIn-houseFull-timeManager
2 days ago
Alkermes logo

Regional Brand Manager, Rare Disease - Southeast / Mid-Atlantic

Alkermes

Miami, FL (Remote)

$200K/yr - $220K/yrIn-houseFull-timeSenior level
2 days ago
Alkermes logo

Regional Brand Manager, Rare Disease - Ohio Valley / Northeast

Alkermes

Boston, MA (Remote)

$200K/yr - $220K/yrIn-houseFull-timeMid level
2 days ago
Alkermes logo

Associate Director, HCP Marketing, LUMRYZ (IH)

Alkermes

Waltham, MA (Hybrid)

$165K/yr - $190K/yrIn-houseFull-timeManager
7 weeks ago
Alkermes logo

Director, Thought Leader Engagement Marketing

Alkermes

Waltham, MA (Hybrid)

$177K/yr - $210K/yrIn-houseFull-timeDirector/executive
4 months ago
Alkermes logo

Intern, Vivitrol Marketing

Alkermes

Waltham, MA (Hybrid)

$21/hr - $24/hrIn-houseFull-timeIntern/new grad
4 months ago
Alkermes logo
Alkermes

Regional Brand Manager, Rare Disease - West

Los Angeles, CA (Remote)

$200K/yr – $220K/yrMid LevelFull time

Posted 2 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own and grow the Sleep brand through field-based engagement, strategic execution, leadership, and cross-functional collaboration to position Alkermes as the leader in rare sleep medicine.

  • Own regional brand growth and field execution
  • Partner across the Commercial Team to align strategy and insights

Job Description

Responsibilities

  • The Regional Brand Manager (RBM) is an integral member of the Sleep marketing team, supporting the continued growth of the brand.
  • The RBM role is field based, with high expectations for customer engagement, strategic execution, leadership, collaboration, and insights gathering.
  • The RBM role will partner across the Commercial Team to execute the brand strategy, positioning Alkermes as THE leader in rare sleep medicine.
Alkermes logo

Alkermes

4.3 Glassdoor

At Alkermes, we apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We have a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized. Our greatest strengths at Alkermes are our people and our inherent empathy for patients, families and caregivers. Neurological and psychiatric disorders strike people at the core of who they are and impact many facets of their lives. We work with urgency to develop new treatment options for people living with these conditions.Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers and broader impacted communities. We remain committed to patient engagement, responsible and sustainable operations, and equitable access to quality treatment.Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.See our Community Guidelines: https://www.alkermes.com/social-community-guidelines

Founded in 1987
Dublin, County Dublin, IRL
2.2K employees (88 in marketing)
www.alkermes.com
85% recommend to a friend
89% CEO approval

Traffic Signals

Monthly Visitors
19.1K
Monthly Google Ads Budget
$32K
Traffic Source Mix
Search
38.1%
Direct
42.1%
Referral
15.8%
Social
1.7%
Paid
2.1%

Headcount Trend

Current headcount: ~2.2K

Marketing Team

Marketing Team Size
81 (4% of company)
Median Career Experience
20 years
Median Tenure
6.8 years
Marketing Roles Posted (Last 30 Days)
4

People

Marketing Leadership

Saru Wade
Saru Wade
Vice President, Brand Lead - LYBALVI (olanzapine and samidorphan)
At the company for 13 years 11 months
Jed Rosenbaum
Jed Rosenbaum
Vice President, Marketing
At the company for 5 years 10 months
Janine Shea
Janine Shea
Vice President Market Access Strategy and Marketing
At the company for 12 years 9 months
Joe Bazerghi
Joe Bazerghi
Vice President Marketing and CNS Franchise Leader
At the company for 18 years 5 months

Funding

Total Funding
$250M
Last Raise
$250M
Post IPO Equity, 8 years ago

Funding History

  • Nov 2017
    Post IPO Equity
  • Jan 2014
    Post IPO Equity • $250M

Recent News

Alkermes to Participate in Two Upcoming Investor Conferences
Nov 25, 2025 • Yahoo Finance
How Analysts See the Alkermes Story Changing After Acquisition Moves and New Narcolepsy Data
Nov 22, 2025 • Yahoo Finance
Dispatches from Jefferies: Why Alkermes wants Avadel, Light Chain’s hope for CD47, and more
Nov 20, 2025 • Endpoints News
Alkermes prevails over Lundbeck in Avadel bidding war
Nov 19, 2025 • Pharmaceutical Technology
Avadel board backs Alkermes' higher offer over Lundbeck proposal
Nov 19, 2025 • Reuters
UPDATE: Avadel Accepts Alkermes’ Revised $2.37B Counteroffer, Besting Lundbeck
Nov 19, 2025 • BioSpace
Avadel Pharmaceuticals Agrees to Alkermes’ Revised Acquisition Offer
Nov 19, 2025 • PharmExec.com
Alkermes Ups Bid for Avadel to $2.37 Billion After Rival Offer
Nov 19, 2025 • Contract Pharma
After Lundbeck's surprise bid, Alkermes sweetens deal to acquire Avadel
Nov 19, 2025 • Fierce Pharma
Alkermes offers more for Avadel after Lundbeck bid
Nov 19, 2025 • pharmaphorum
Alkermes sweetens Avadel bid in effort to stave off rival Lundbeck
Nov 19, 2025 • FirstWord Pharma
Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc
Nov 19, 2025 • PR Newswire
Alkermes Increases Offer to Acquire Avadel
Nov 19, 2025 • Sleep Review
TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment
Nov 19, 2025 • Yahoo Finance
Avadel views Lundbeck's $2.4B buyout offer as 'superior,' kicking the ball back to Alkermes' court
Nov 18, 2025 • Fierce Pharma
Lundbeck tries to upend Alkermes' takeout of sleep drug developer Avadel
Nov 14, 2025 • FirstWord Pharma
Alkermes Response to Avadel Announcement
Nov 14, 2025 • PR Newswire
To Wall Street, a new bidding war puts Alkermes in a tough spot
Nov 14, 2025 • BioPharma Dive
Lundbeck disrupts Alkermes' planned $2.1B purchase of Avadel with higher bid
Nov 14, 2025 • Fierce Pharma
A Look at Alkermes's Valuation Following Positive Phase 2 Alixorexton Results in Narcolepsy Type 2
Nov 13, 2025 • Yahoo Finance
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
Nov 13, 2025 • BioSpace
Alkermes races to phase 3 after posting another narcolepsy win
Nov 12, 2025 • Fierce Biotech
Alkermes’ Alixorexton Shows Positive Phase II Results in Narcolepsy Type 2
Nov 12, 2025 • Applied Clinical Trials Online
Alkermes breaks new ground in narcolepsy with orexin drug
Nov 12, 2025 • pharmaphorum
Narcolepsy race heats up with Alkermes’ OX2R NT2 data but investors spooked
Nov 12, 2025 • Clinical Trials Arena
How Recent Developments Are Changing the Alkermes Investment Story
Nov 8, 2025 • Yahoo Finance
Is Alkermes (ALKS) Stock Outpacing Its Medical Peers This Year?
Nov 6, 2025 • Yahoo Finance
Analysts Just Made An Incredible Upgrade To Their Alkermes plc (NASDAQ:ALKS) Forecasts
Nov 5, 2025 • Yahoo Finance
Alkermes plc Just Recorded A 62% EPS Beat: Here's What Analysts Are Forecasting Next
Oct 31, 2025 • simplywall.st
Alkermes PLC (ALKS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
Oct 30, 2025 • Yahoo Finance
Alkermes Q3 Earnings and Revenues Beat Estimates, 2025 View Raised
Oct 29, 2025 • Yahoo Finance
Alkermes (ALKS) Surpasses Q3 Earnings and Revenue Estimates
Oct 28, 2025 • Yahoo Finance
Alkermes plc Reports Third Quarter 2025 Financial Results
Oct 28, 2025 • PR Newswire
Earnings To Watch: Alkermes PLC (ALKS) Reports Q3 2025 Result
Oct 27, 2025 • Yahoo Finance
How Do Recent Clinical Trial Updates Impact Alkermes Valuation in 2025?
Oct 26, 2025 • simplywall.st
Alkermes to Acquire Avadel, Adding LUMRYZ to Its Portfolio
Oct 25, 2025 • Sleep Review
Alkermes Plc expected to post earnings of 30 cents a share - Earnings Preview
Oct 24, 2025 • TradingView
Looking at the Narrative for Avadel After the Alkermes Acquisition and Analyst Reactions
Oct 23, 2025 • Yahoo Finance
Alkermes’ up to $2.1B Purchase of Avadel Sets Groundwork for ‘Strategic Evolution’
Oct 23, 2025 • BioSpace
Alkermes to acquire Avadel for $2.1bn
Oct 23, 2025 • Pharmaceutical Technology
Alkermes to acquire Avadel
Oct 23, 2025 • The Pharma Letter
Alkermes buys Avadel for €1.81bn in one of Ireland’s largest pharma deals of the year
Oct 23, 2025 • Business Post
Alkermes plc Acquiring Avadel Pharmaceuticals in $2.1 Billion Definitive Agreement
Oct 23, 2025 • PharmExec.com
Alkermes Makes $2.1 Billion Bet On Sleep Medicine
Oct 22, 2025 • Finimize
Alkermes bets $2.1bn on Avadel and its narcolepsy drug
Oct 22, 2025 • pharmaphorum
Alkermes expands sleep portfolio with acquisition worth up to $2.1B
Oct 22, 2025 • BioPharma Dive
Avadel Pharmaceuticals stock rises on $2.1 billion acquisition by Alkermes
Oct 22, 2025 • Investing.com
Alkermes Buys Avadel For $2.1 Billion To Enter Sleep Medicine
Oct 22, 2025 • Finimize
Alkermes enters sleep medicine market with $2.1 billion Avadel deal
Oct 22, 2025 • Yahoo Finance
Alkermes to acquire Avadel for up to $2.1 billion
Oct 22, 2025 • Yahoo Finance
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
Oct 22, 2025 • PR Newswire
Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
Oct 22, 2025 • Sahm
No nap gap: Alkermes to sleep market early via $2.1B Avadel buy
Oct 22, 2025 • BioWorld MedTech
Alkermes plots $2.1B acquisition of Avadel and its long-acting narcolepsy drug Lumryz
Oct 22, 2025 • Fierce Pharma
Why Alkermes' $2.1 Billion Avadel Buyout Was 'Very Confusing' — At First
Oct 22, 2025 • Investor's Business Daily
Alkermes to Acquire Avadel Pharmaceuticals for $2.1 Billion
Oct 22, 2025 • Contract Pharma
Alkermes enters sleep medicine market with $2.1 billion Avadel deal
Oct 22, 2025 • Reuters
Alkermes builds out sleep portfolio with $2.1B Avadel takeout
Oct 22, 2025 • FirstWord Pharma
How The Avadel Deal and Clinical News Are Shaping the Alkermes Investment Story
Oct 22, 2025 • Yahoo Finance
Wall Street Analysts Predict a 34.8% Upside in Alkermes (ALKS): Here's What You Should Know
Oct 21, 2025 • Yahoo Finance
Alkermes to Report Third Quarter Financial Results on October 28, 2025
Oct 20, 2025 • Yahoo Finance
Assessing Alkermes (ALKS) Valuation Following Recent Share Price Momentum
Oct 18, 2025 • simplywall.st
Aug Summary: Is Alkermes plc stock a contrarian buy - 2025 Macro Impact & Short-Term High Return Ideas
Oct 17, 2025 • Trung tâm Dự báo KTTV quốc gia
Will Alkermes plc stock maintain growth story - 2025 EndofYear Setup & Risk Controlled Stock Pick Alerts
Oct 17, 2025 • Trung tâm Dự báo KTTV quốc gia
Will Alkermes plc stock maintain growth story - 2025 Growth vs Value & Accurate Technical Buy Alerts
Oct 17, 2025 • Trung tâm Dự báo KTTV quốc gia
Earnings call transcript: Alkermes Plc forecasts strong proprietary sales in Q2 2025
Oct 14, 2025 • Investing.com
What Do Recent Gains Mean for Alkermes Stock Value in 2025?
Oct 9, 2025 • simplywall.st
Alkermes sued over alleged scheme to block generic Vivitrol
Oct 3, 2025 • Reuters
Is Alkermes' (ALKS) Narcolepsy Drug Breakthrough Shifting Its Investment Narrative?
Sep 28, 2025 • Yahoo Finance
HC Wainwright Affirms Alkermes (ALKS) ‘Neutral’ Rating on Vibrance-1 Phase 2 Study
Sep 18, 2025 • Yahoo Finance
STAT+: Experimental narcolepsy drugs bring hope to patients: ‘as close as one could get to living a near-normal life’
Sep 17, 2025 • STAT
‘As close as one could get to living a near-normal life’: Experimental narcolepsy drugs bring hope to patients
Sep 16, 2025 • Boston Globe
Appointments and advancements for Sept. 15, 2025
Sep 15, 2025 • BioWorld Financial Watch
Alkermes Names Joshua Reed Chief Financial Officer
Sep 12, 2025 • Contract Pharma
Alkermes Names Joshua Reed CFO
Sep 12, 2025 • MarketScreener
Alkermes says on Sept 9, unit granted Amneal rights to sell generic version of Vivitrol - SEC filing
Sep 12, 2025 • MarketScreener
Alkermes Appoints Joshua Reed as Chief Financial Officer
Sep 12, 2025 • Morningstar.com
Alkermes names Joshua Reed as CFO
Sep 12, 2025 • thefly.com
Alkermes Appoints Joshua Reed as Chief Financial Officer
Sep 12, 2025 • PR Newswire UK
Alkermes Files Patent Litigation Against Teva, Apotex, MSN Pharmaceuticals
Sep 12, 2025 • Morningstar.com
Alkermes Files Patent Litigation Against Teva, Apotex, MSN Pharmaceuticals
Sep 12, 2025 • MarketScreener
Alkermes Appoints Joshua Reed as Chief Financial Officer
Sep 12, 2025 • PR Newswire
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
Sep 11, 2025 • PR Newswire
Alkermes Announces Launch of 8th Annual Alkermes Pathways Research Awards® Program
Sep 11, 2025 • Nasdaq
Questions remain after Alkermes narcolepsy data, says H.C. Wainwright
Sep 9, 2025 • thefly.com
Takeda and Alkermes share OX2R drug data for narcolepsy
Sep 8, 2025 • Clinical Trials Arena
Takeda, Alkermes lift lid on data for rival narcolepsy hopefuls as race to market heats up
Sep 8, 2025 • Fierce Biotech
#WorldSleep2025: Alkermes’ success in Phase 2 narcolepsy trial is clouded by side effects
Sep 8, 2025 • Endpoints News
Alkermes, Takeda show encouraging data on narcolepsy drugs | STAT
Sep 8, 2025 • statnews.com
Alkermes, Takeda detail results underpinning orexin drugs for narcolepsy
Sep 8, 2025 • FirstWord Pharma
Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025
Sep 8, 2025 • MarketScreener
Takeda Is Waking Up the Narcolepsy Market With First-in-Class Drug, But Alkermes Is on Its Heels
Sep 8, 2025 • MedCity News
Alkermes narcolepsy data 'solid,' about as expected, says Leerink
Sep 8, 2025 • thefly.com
Alkermes One Ups Takeda in Narcolepsy, Clearing Cognitive Impairments in Mid-Stage Trial
Sep 8, 2025 • BioSpace
Jefferies says stage set for Centessa to differentiate in narcolepsy
Sep 8, 2025 • thefly.com
Alkermes Investigational Narcolepsy Drug Meets Primary, Secondary Endpoints in Phase 2 Study
Sep 8, 2025 • MarketScreener
Alkermes presents detailed positive results from Vibrance-1 Phase 2 Study of Alixorextin in patients with narcolepsy type 1
Sep 8, 2025 • MarketScreener
Alkermes narcolepsy type 1 data largely as expected, says Mizuho
Sep 8, 2025 • thefly.com
Alkermes Presents Detailed Positive Results From Vibrance-1 Phase 2 Study Of Alixorexton In Patients With Narcolepsy Type 1
Sep 8, 2025 • Reuters
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
Sep 3, 2025 • Benzinga.com